The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus

Journal of Rheumatology

Volumn 31, Issue 8, 2004, Pages 1551-1556

  Duffy, Emeir M ^a   Meenagh, Gary K ^b   McMillan, Stanley A ^c   Strain, John J ^a   Hannigan, Bernadette M ^a   Bell, Aubrey L ^b,d  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

^d MUSGRAVE PARK HOSPITAL   (United Kingdom)

Author keywords

Benzylamine oxidase; Copper revised systemic lupus disease activity measure; Fish oil; Systemic lupus erythematosus

Indexed keywords

COPPER; FISH OIL; OMEGA 3 FATTY ACID;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COLLAGEN DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; COPPER; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FEMALE; FISH OILS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 3442892957     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Corman LC. The role of diet in animal models of systemic lupus erythematosus; possible implications for human lupus. Semin Arthritis Rheum 1985;15:61-9.
2. Parke AL, Parke DV. Diet and nutrition in rheumatoid arthritis and other chronic inflammatory diseases. J Clin Biochem 1996;20:1-26.
3. Danao-Camara TC, Shintani TT. The dietary treatment of inflammatory arthritis: case reports and review of the literature. Hawaii Med J 1999;58:126-31.
4. Brown AC. Lupus erythematosus and nutrition: a review of literature. J Ren Nutr 2000;10:170-83.
5. Leiba A, Amital H, Gershwin ME, Shoenfeld Y. Diet and lupus [review]. Lupus 2001;10:246-8.
6. Chandrasekar B, Fernandes G. Decreased pro-inflammatory cytokines and increased antioxidant enzyme gene expression by omega-3 lipids in murine lupus nephritis. Biochem Biophys Res Commun 1994;200:893-8.
7. Chandrasekar B, Troyer DA, Venkatraman JT, Fernandes G. Dietary omega-3 lipids delay the onset and progression of autoimmune lupus nephritis by inhibiting transforming growth factor beta mRNA and protein expression. J Autoimmun 1995;8:381-93.
8. Chandrasekar B, Troyer DA, Venkatraman JT, Fernandes G. Tissue specific regulation of transforming growth factor beta by omega-3 lipid-fish krill oil in autoimmune murine lupus. Nutr Res 1996;16:489-503.
9. Venkatraman JT, Chandrasekar B, Kim JD, Fernandes G. Effect of n-3 and n-6 fatty acids on the activities and expression of hepatic antioxidant enzymes in autoimmune-prone NZB x NZW F1 mice. Lipids 1994;29:561-8.
10. Fernandes G, Bysari C, Venkatraman JT, Tomar V, Zhoa W. Increased TGF-beta and decreased oncogene expression by omega-3 fatty acids in the spleen delays onset of autoimmune disease in B/W mice. J Immunol 1994;15:5979-87.
11. Spurney RF, Ruiz P, Albrightson CR, Pisetsky DS, Coffman TM. Fish oil feeding modulates leukotriene production in murine lupus nephritis. Prostaglandins 1994;48:331-48.
12. Robinson DR, Tateno S, Kneoll C, et al. Dietary marine lipids suppress murine autoimmune disease. J Intern Med 1989;225 Suppl:211-6.
13. Robinson DR, Xu LL, Tateno S, Guo M, Colvin RB. Suppression of autoimmune disease by dietary n-3 fatty acids. J Lipid Res 1993;34:1435-44.
14. Robinson DR, Xu LL, Knoell CT, et al. Alleviation of autoimmune disease by omega-3 fatty acids. World Rev Nutr Diet 1994;76:95-102.
15. Berger A, German JB, Gershwin ME. Implications of modifying cardiolipin acyl composition by diet. 1. Cardiolipin acyl chain is an important determinant in the binding to antiphospholipid antibodies in SLE sera. J Autoimmun 1992;5:229-41.
16. Godfrey DG, Stimson WH, Watson J, Belch J, Sturrock RD. Effects of dietary supplementation on autoimmunity in the MRL/lpr mouse: a preliminary investigation. Ann Rheum Dis 1986;45:1019-24.
17. Yumura W, Hattori S, Morrow WJW, Mayes DC, Levy JA, Shirai T. Dietary fat and immune function. II. Effects on immune complex nephritis in (NZB x NZW) F1 mice. J Immunol 1985;135:3864-8.
18. Prickett JD, Robinson DR, Steinberg AD. Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB x NZW F1 mice. J Clin Invest 1981;68:556-9.
19. Walton AJE, Snaith ML, Locniskar M, Cumberland AG, Morrow WJW, Isenberg DA. Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis 1991;50:463-6.
20. Clark WF, Parbtani A, Huff MW, Reid B, Holub BJ, Falardeau P. Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. Kidney Int 1989;36:653-60.
21. Clark WF, Parbtani A, Naylor CD, et al. Fish oil in lupus nephritis: clinical findings and methodological implications. Kidney Int 1993;44:75-86.
22. Minami Y, Sasaki T, Komatsu S, et al. Female systemic lupus erythematosus in Miyagi prefecture, Japan: A case-control study of dietary and reproductive factors. Tohoku J Exp Med 1993;169:245-52.
23. Das UN. Beneficial effect of eicosapentaenoic acid and docosahexaenoic acids in the management of systemic lupus erythematosus and its relationship to the cytokine network. Prostaglandins Leukot Essent Fatty Acids 1994;51:207-13.
24. Mohan JK, Das UN. Oxidant stress, anti-oxidants and essential fatty acids in systemic lupus erythematosus. Prost Leukot Essent Fatty Acids 1997;56:193-8.
25. Westberg G, Tarkowski A. Effect of MaxEPA in patients with SLE. Scand J Rheumatol 1990;19:137-43.
26. Powanda MC. Trace elements in the pathogenesis and treatment of inflammatory conditions. Agents Actions 1981;8:121-3.
27. Sorenson JR. Copper complexes offer a physiological approach to treatment of chronic diseases. Prog Med Chem 1989;26:437-568.
28. Jendryczko A, Drozdz M, Magner K. Antilupus activity of copper (II). Exp Pathol 1985;28:187-9.
29. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982;25:1271-7.
30. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
31. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA 2003;289:2545-53.
32. Turnlund JR. Copper. In: Shils ME, Olson JA, Shike M, editors. Modern nutrition in health and disease. Philadelphia: Lea & Febiger; 1994:231.
33. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
34. Fortin PR, Abrahamowicz M, Clarke AE, et al. Do lupus disease activity measures detect clinically important change? J Rheumatol 2000;27:1421-8.
35. Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001;10:405-9.
36. Crawley H. Food portion sizes. 3rd ed. London: HMSO. 1992.
37. Moore AD, Joseph L. Sample size considerations for superiority trials in systemic lupus erythematosus (SLE). Lupus 1999;8:612-9.
38. Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996;39:370-8.
39. Horak P, Scudla V, Hermanovo Z, et al. Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus. Clin Rheumatol 2001;20:337-44.
40. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 1979;66:210-5.
41. Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992;35:311-8.
42. James MJ, Gibson R, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000;71:343S-348S.
43. Ergas D, Eilat E, Mendlovic S, Sthoeger ZM. Omega-3 fatty acids and the immune system in autoimmunity. Isr Med Assoc J 2002;4:34-8.
44. Lee TH, Hoover RL, William JD, et al. Effect of dietary enrichment with eicosapentaenoic acid and docosahexaenoic acid on in vivo neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 1985;312:1217-24.
45. Sorenson JRJ. Copper complexes for therapy of cancer and autoimmune diseases. In: Rainsford KD, Milanino R, Sorenson, JRJ, Velo GP, editors. Copper and zinc in inflammatory and degenerative diseases. Dordrecht: Kluwer Academic Publishers; 1998.